Compounds > motapizone
Page last updated: 2024-08-24

motapizone and zaprinast

motapizone has been researched along with zaprinast in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (66.67)18.2507
2000's1 (33.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dent, G; Magnussen, H; Nakashima, M; Rabe, KF; Schudt, C; Tenor, H1
Enke, B; Ghofrani, HA; Grimminger, F; Schermuly, RT; Schudt, C; Seeger, W; Walmrath, D; Weissmann, N1
Dunkern, TR; Hatzelmann, A1

Other Studies

3 other study(ies) available for motapizone and zaprinast

ArticleYear
Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors.
    The American journal of physiology, 1994, Volume: 266, Issue:5 Pt 1

    Topics: 1-Methyl-3-isobutylxanthine; Adult; Aged; Antihypertensive Agents; Carbachol; Colforsin; Cytosol; Dinoprost; Dose-Response Relationship, Drug; Female; Humans; Isoenzymes; Kinetics; Lung Neoplasms; Male; Middle Aged; Muscle Contraction; Muscle Relaxation; Muscle Tonus; Muscle, Smooth, Vascular; Nitroprusside; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pulmonary Artery; Purinones; Pyridazines; Pyrrolidinones; Rolipram

1994
Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension.
    American journal of respiratory and critical care medicine, 1999, Volume: 160, Issue:5 Pt 1

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Administration, Inhalation; Aerosols; Animals; Antihypertensive Agents; Blood Pressure; Cardiac Output; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epoprostenol; Hypertension, Pulmonary; Naphthyridines; Phosphodiesterase Inhibitors; Pulmonary Circulation; Purinones; Pyridazines; Rabbits; Rolipram; Vasoconstrictor Agents; Vasodilation

1999
The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5.
    Cellular signalling, 2005, Volume: 17, Issue:3

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Blood Platelets; Cyclic AMP; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 5; Humans; In Vitro Techniques; Nitric Oxide Donors; Nitroprusside; Phosphodiesterase I; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Platelet Activation; Platelet-Derived Growth Factor; Purines; Purinones; Pyridazines; Serotonin; Sildenafil Citrate; Sulfones

2005